US › Healthcare

Atossa Genetics Inc (ATOS)

US · Healthcare · Biotechnology

$2.40-0.83%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-8.5M

EPS

$-0.95

EPS estimate

$-1.04

EPS came in at -0.95 against a street estimate of -1.04 — a beat of 8.7%.

Key statistics

Market cap

$25.0M

Forward P/E

7.0

P/B

0.87

Book value

$2.69

EPS (TTM)

$-4.34

52-week high

$19.35

52-week low

$1.70

50-day MA

$2.43

200-day MA

$5.45

Beta

1.27

Analyst view

Analysts rate Atossa Genetics Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $18.67.

Shareholding

Insiders

1.85%

Institutions

17.38%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.50%
Ameriprise Financial Inc	2.56%
BlackRock Inc	1.33%
Renaissance Technologies Corp	1.09%
Geode Capital Management, LLC	0.97%
UBS Group AG	0.92%
Vanguard Fiduciary Trust Co	0.52%
Millennium Management LLC	0.47%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Atossa Genetics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.